In the UK and across the EU, injured persons have more options than in the US

Suing Pharma directly is possible. But not in the US.

A couple of weeks ago, several news articles reporting on an attorney, representing nearly 50 individuals, announcing his clients will be suing AstraZeneca (AZ), as the result of C19 jab injuries and death.

The lead case, Alpa Tailor vs AstraZeneca, was brought on behalf of her husband Anish and their children. Alpa died after receiving her first dose of AZ. She developed fatal blood clots in her brain. Her husband filed a product liability suit against AZ at London’s High Court August 4, 2023.

Jamie Scott filed a product liability suit against AZ after developing vaccine-induced thrombocytopenia (blood clotting).

Both of these cases are the first lawsuits brought in England and Wales as the result of serious adverse reactions to the C19 jab.

Peter Todd, attorney representing the Tailors, told me in a zoom interview he will have nearly 50 more cases to file later this year.

Sarah Moore, attorney representing Jamie Scott told The BMJ “While the VDPS payments are very modest in amount, and will do very little to alleviate the financial difficulties with which many families are now struggling as a consequence of injury or bereavement, the fact of payment for some will mark a moment of vindication in that it is the clearest statement yet, by the government, that in some rare instances the Covid-19 vaccines have caused very significant injury or death.”

Moore continues “the inadequacies of the scheme mean that some families will have no choice but to look at litigation in order to access substantive financial support”.

In the UK, vaccine injured persons traditionally file for compensation in the statutory compensation scheme. The program if the case is found to be compensable would receive a one time payment capped at £120 000 or $150,000. A person needs to be at least 60% permanently disabled.

You may recall the story of Zion, the UK rockstar that died 14 days after receiving his first AstraZeneca vaccine from a fatal blood clot in his brain.

This is the most common pathway for injured persons or their estates to file for compensation.

Filing a product liability suit is an option to all injured persons. However, the legal process may take many years to resolve or adjudicate. But it an option that is not available to person in the US. The CICP so far has awarded 4 cases reimbursement costs of medical care not covered by private insurance or other benefits.

Anna Morris, speaking at the British Inquiry model 4 for vaccines and therapeutics this week, told the inquiry that as of July 2023, the scheme has received a total of 6,399 claims of which 2,352 have been notified of an outcome. Approval or dismissal.

There are over 500 claims waiting for more than 12 months with 166 of them waiting over 18 months. Only 127 claims have received an award.

Meanwhile in the US, there are over 12,000 petitions filed in the CICP and only 5 have been deemed compensable as of August 1, 2023. One of them did not have any expenses associated with care, thus no check was sent to the petitioner.

In the CICP, we do not know how many days each petition has been awaiting processing. HRSA will not disclose most information. The lack of transparency in the CICP is some of the worst examples of our government. We knew more about the secret bombings during the Vietnam War than we do with the CICP.

Keep learning, keep challenging yourself and always, always question authority.